We are studying the safety and early effectiveness of AZD9574, both alone and with other cancer therapies, for patients with advanced solid tumors. This research aims to improve treatment options for those facing these challenging conditions.
Health conditions and diseases that the clinical trial is designed to study and treat.
This condition refers to advanced or relapsed stages of ovarian, breast, pancreatic, or prostate cancer, particularly in patients with mutations in genes like BRCA1, BRCA2, PALB2, RAD51C, or RAD51D.
This condition involves advanced, unresectable solid tumors that are HER2-positive, including non-small cell lung cancer (NSCLC) with HER2 activating mutations.
This condition encompasses advanced, unresectable, or metastatic solid tumors in breast, endometrial, ovarian, and prostate cancers.
This condition includes advanced or relapsed HER2-negative breast, ovarian, prostate, or pancreatic cancers, particularly in patients with specific genetic mutations.
IDH-mutant glioma is a type of brain tumor characterized by mutations in the IDH gene, which can affect treatment options and prognosis.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
